Larvol Delta - PROPEL-Infant-and-Toddler-Study-design-and-ongoing-enrollment-of-a-phase-22b-study-of-infigratinib-in-children-under-3-years-old-with-achondroplasia

Truseltiq (infigratinib) - BridgeBio, Pfizer, Xediton Pharma

https://pag.virtual-meeting.org/RELEASE/espe2026/en-GB/pag/presentation/748673

Dr. Melita Irving

Sep 5, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next